Skip to main content
. Author manuscript; available in PMC: 2023 Apr 12.
Published in final edited form as: Leukemia. 2022 Jan 12;36(4):946–955. doi: 10.1038/s41375-021-01505-w

Figure 1. ARID1B and ARID2 in human AML.

Figure 1

(A) Graphical representation of ARID1B and ARID2 mutations identified in primary AML patient samples in the OSHU AML cohort. (B) Survival curve of de novo non-MRC (Mylodysplasia-Related Changes) AML patients with or without mutation in ARID1B or ARID2 from the OSHU AML cohort. (C,D) Survival curves of de novo non-MRC AML patients in the OSHU AML cohort and primary AML patients from the TCGA AML data set stratified by high and low expression of ARID1B (C) or ARID2 (D). Expression is stratified using Z score from cBioPortal34,35.